β-amyloid, microglia, and the inflammasome in Alzheimer’s disease

Seminars in Immunopathology

Volumn 37, Issue 6, 2015, Pages 607-611

  Gold, Maike ^a   El Khoury, Joseph ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer s disease; Macrophage; Microglia; NLRP3 inflammasome; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; CATHEPSIN B; CD36 ANTIGEN; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; PURINERGIC P2X7 RECEPTOR; CARRIER PROTEIN; CYTOKINE; NLRP3 PROTEIN, HUMAN;

ALZHEIMER DISEASE; CELL DEGENERATION; CELL FUNCTION; DISEASE COURSE; ENZYME ACTIVATION; HUMAN; MICROGLIA; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; BRAIN; CYTOLOGY; IMMUNOLOGY; MACROPHAGE; METABOLISM; MONOCYTE; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; CARRIER PROTEINS; CYTOKINES; HUMANS; INFLAMMASOMES; MACROPHAGES; MICROGLIA; MONOCYTES; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; PHAGOCYTOSIS;

EID: 84945438257     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-015-0518-0     Document Type: Review

References (61)

1. McGeer PL et al (1987) Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 79(1-2):195–200
2. Rozemuller JM, Eikelenboom P, Stam FC (1986) Role of microglia in plaque formation in senile dementia of the Alzheimer type. An immunohistochemical study. Virchows Arch B Cell Pathol Incl Mol Pathol 51(3):247–54
3. Frautschy SA et al (1998) Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 152(1):307–17
4. Hickman SE, Allison EK, El Khoury J (2008) Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 28(33):8354–60
5. El Khoury J (2010) Neurodegeneration and the neuroimmune system. Nat Med 16(12):1369–70
6. Kettenmann H et al (2011) Physiology of microglia. Physiol Rev 91(2):461–553
7. El Khoury J, Luster AD (2008) Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. Trends Pharmacol Sci 29(12):626–32
8. El Khoury J et al (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13(4):432–8
9. El Khoury JB et al (2003) CD36 mediates the innate host response to beta-amyloid. J Exp Med 197(12):1657–66
10. Frenkel D et al (2013) Scara1 deficiency impairs clearance of soluble amyloid-beta by mononuclear phagocytes and accelerates Alzheimer's-like disease progression. Nat Commun 4:2030
11. Stewart CR et al (2010) CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 11(2):155–61
12. Halle A et al (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9(8):857–65
13. Heneka MT et al (2013) NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493(7434):674–8
14. Sheedy FJ et al (2013) CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol 14(8):812–20
15. Lawson LJ et al (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39(1):151–70
16. Hickman SE et al (2013) The microglial sensome revealed by direct RNA sequencing. Nat Neurosci 16(12):1896–905
17. Stence N, Waite M, Dailey ME (2001) Dynamics of microglial activation: a confocal time-lapse analysis in hippocampal slices. Glia 33(3):256–66
18. Mogi M et al (1994) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from Parkinsonian patients. Neurosci Lett 180(2):147–50
19. Morimoto K et al (2011) Expression profiles of cytokines in the brains of Alzheimer's disease (AD) patients compared to the brains of non-demented patients with and without increasing AD pathology. J Alzheimers Dis 25(1):59–76
20. Stoeck K, Bodemer M, Zerr I (2006) Pro- and anti-inflammatory cytokines in the CSF of patients with Creutzfeldt-Jakob disease. J Neuroimmunol 172(1-2):175–81
21. Coraci IS et al (2002) CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am J Pathol 160(1):101–12
22. Cunningham C (2013) Microglia and neurodegeneration: the role of systemic inflammation. Glia 61(1):71–90
23. Cho S et al (2001) Repression of proinflammatory cytokine and inducible nitric oxide synthase (NOS2) gene expression in activated microglia by N-acetyl-O-methyldopamine: protein kinase A-dependent mechanism. Glia 33(4):324–33
24. Yates SL et al (2000) Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia. J Neurochem 74(3):1017–25
25. Goodwin JL, Kehrli ME Jr, Uemura E (1997) Integrin Mac-1 and beta-amyloid in microglial release of nitric oxide. Brain Res 768(1-2):279–86
26. Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10(2):417–26
27. Boyden ED, Dietrich WF (2006) Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet 38(2):240–4
28. Mariathasan S et al (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440(7081):228–32
29. Mariathasan S et al (2004) Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430(6996):213–8
30. Rathinam VA et al (2010) The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 11(5):395–402
31. Gross O et al (2009) Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 459(7245):433–6
32. Rathinam VA et al (2012) TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria. Cell 150(3):606–19
33. Martinon F et al (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081):237–41
34. Duewell P et al (2010) NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464(7293):1357–61
35. Garlanda C, Dinarello CA, Mantovani A (2013) The interleukin-1 family: back to the future. Immunity 39(6):1003–18
36. Lynch MA (2010) Age-related neuroinflammatory changes negatively impact on neuronal function. Front Aging Neurosci 1:6
37. Bauernfeind FG et al (2009) Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 183(2):787–91
38. Franchi L, Eigenbrod T, Nunez G (2009) Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J Immunol 183(2):792–6
39. Chow JC et al (1999) Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 274(16):10689–92
40. Juliana C et al (2012) Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem 287(43):36617–22
41. Duncan JA et al (2007) Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. Proc Natl Acad Sci U S A 104(19):8041–6
42. Srinivasula SM et al (2002) The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. J Biol Chem 277(24):21119–22
43. Baroja-Mazo A et al (2014) The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol 15(8):738–48
44. Franklin BS et al (2014) The adaptor ASC has extracellular and ‘prionoid’ activities that propagate inflammation. Nat Immunol 15(8):727–37
45. Yan Y et al (2015) Dopamine Controls Systemic Inflammation through Inhibition of NLRP3 Inflammasome. Cell 160(1-2):62–73
46. Sarkar C et al (2010) The immunoregulatory role of dopamine: an update. Brain Behav Immun 24(4):525–8
47. Lee GS et al (2012) The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature 492(7427):123–7
48. Coll RC et al (2015) A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 21(3):248–255
49. Griffin WS et al (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 86(19):7611–5
50. Murphy N, Grehan B, Lynch MA (2014) Glial uptake of amyloid beta induces NLRP3 inflammasome formation via cathepsin-dependent degradation of NLRP10. Neuromol Med 16(1):205–15
51. Kahlenberg JM, Dubyak GR (2004) Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release. Am J Physiol Cell Physiol 286(5):C1100–8
52. McLarnon JG et al (2006) Upregulated expression of purinergic P2X(7) receptor in Alzheimer disease and amyloid-beta peptide-treated microglia and in peptide-injected rat hippocampus. J Neuropathol Exp Neurol 65(11):1090–7
53. Kahlenberg JM et al (2005) Potentiation of caspase-1 activation by the P2X7 receptor is dependent on TLR signals and requires NF-kappaB-driven protein synthesis. J Immunol 175(11):7611–22
54. Wegiel J et al (2003) Origin and turnover of microglial cells in fibrillar plaques of APPsw transgenic mice. Acta Neuropathol 105(4):393–402
55. Lebson L et al (2010) Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. J Neurosci 30(29):9651–8
56. Bennett JL et al (2003) CCL2 transgene expression in the central nervous system directs diffuse infiltration of CD45(high)CD11b(+) monocytes and enhanced Theiler's murine encephalomyelitis virus-induced demyelinating disease. J Neurovirol 9(6):623–36
57. Sedgwick JD et al (1991) Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc Natl Acad Sci U S A 88(16):7438–42
58. Saederup N et al (2010) Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One 5(10):e13693
59. Naert G, Rivest S (2012) Hematopoietic CC-chemokine receptor 2 (CCR2) competent cells are protective for the cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. Mol Med 18:297–313
60. Jay TR et al (2015) TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med 212(3):287–295
61. Koronyo Y et al (2015) Therapeutic effects of glatiramer acetate and grafted CD115+ monocytes in a mouse model of Alzheimer's disease. Brain 138(8):2399–2422